NASDAQ : TXG
10x Genomics, Inc. — Key statistics
Healthcare · Health Information Services · United States
Last price 81.55 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.63B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.03B |
| Enterprise Value | 7.56B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 120.21M |
| Shares Outstanding | 130.29M |
| Shares Change (YoY) | +4.39% |
| Shares Change (QoQ) | +1.32% |
| Owned by Insiders (%) | 7.79% |
| Owned by Institutions (%) | 99.76% |
| Float | 118.19M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.02 |
| Forward PS | 12.43 |
| PB Ratio | 11.06 |
| P/TBV Ratio | 10.61 |
| P/FCF Ratio | 66.17 |
| P/OCF Ratio | 63.23 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 12.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 62.27 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.69 |
| Quick Ratio | 5.09 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.65 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -9.40% |
| Return on Assets (ROA) | -5.05% |
| Return on Invested Capital (ROIC) | -5.75% |
| Return on Capital Employed (ROCE) | -8.91% |
| Weighted Average Cost of Capital (WACC) | 15.05% |
| Revenue Per Employee | $523,694 |
| Profits Per Employee | -$63,773 |
| Employee Count | 1,178 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 3.03 |
Taxes
| Measure | Value |
|---|
| Income Tax | 235,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.99 |
| 52-Week Price Change | +351.83% |
| 50-Day Moving Average | 74.10 |
| 200-Day Moving Average | 40.78 |
| Relative Strength Index (RSI) | 37.96 |
| Average Volume (20 Days) | 4,178,340 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.73M |
| Short Previous Month | 15.37M |
| Short % of Shares Out | 9.77% |
| Short % of Float | 10.77% |
| Short Ratio (days to cover) | 3.09 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 616.91M |
| Gross Profit | 432.53M |
| Operating Income | -81.18M |
| Pretax Income | -74.89M |
| Net Income | -75.13M |
| EBITDA | -41.20M |
| EBIT | -81.18M |
| Loss Per Share | -$0.59 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 552.03M |
| Total Debt | 78.80M |
| Net Cash | 473.24M |
| Net Cash Per Share | $3.63 |
| Equity (Book Value) | 825.55M |
| Book Value Per Share | 6.34 |
| Working Capital | 556.16M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 127.09M |
| Capital Expenditures | -5.65M |
| Depreciation & Amortization | 39.98M |
| Net Borrowing | n/a |
| Free Cash Flow | 121.44M |
| FCF Per Share | $0.93 |
Margins
| Measure | Value |
|---|
| Gross Margin | 70.11% |
| Operating Margin | -13.16% |
| Pretax Margin | -12.14% |
| Profit Margin | -12.18% |
| EBITDA Margin | -6.68% |
| EBIT Margin | -13.16% |
| FCF Margin | 19.68% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.39% |
| Shareholder Yield | -4.39% |
| Earnings Yield | -0.95% |
| FCF Yield | 1.51% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $77.50 |
| Price Target Difference | 25.75% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 5.56% |
| EPS Growth Forecast (3Y) | 44.32% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.75 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |